Navigation Links
The Journal of Allergy and Clinical Immunology pubblica i dati sulla termoplastica bronchiale che dimostrano una riduzione sostenuta degli attacchi gravi di asma nell'arco di cinque anni
Date:9/9/2013

NATICK, Massachusetts, September 9, 2013 /PRNewswire/ --

I benefici comportati dalla termoplastica bronchiale perdurano per anni, anziché per ore, diversamente da quanto accade col solo trattamento farmacologico.

Una tecnologia rivoluzionaria di Boston Scientific per il trattamento dell'asma grave si è dimostrata sicura ed efficace nell'arco di almeno cinque anni, secondo i dati pubblicati online da un'importante rivista medica.  

The Journal of Allergy and Clinical Immunology, ovvero la rivista scientifica ufficiale della American Academy of Allergy, Asthma & Immunology (AAAAI) e la più citata nel settore dell'allergia e dell'immunologia clinica, ha presentato i dati dallo studio clinico Asthma Intervention Research 2 (AIR2), che valutava la sicurezza e l'efficacia del sistema di termoplastica bronchiale (BT) Alair® di Boston Scientific. I dati a lungo termine si basano su uno studio post-autorizzazione, nel corso del quale i pazienti trattati con BT nello studio AIR2 sono stati seguiti per un totale di cinque anni.  

I principali risultati riportati a cinque anni dopo la procedura di BT includono:

  • La riduzione della percentuale di pazienti trattati con BT che manifestano esacerbazioni gravi (rispetto ai pazienti sottoposti a placebo) è stata mantenuta fino a cinque anni.
  • Nell'arco di cinque anni, è stata osservata una riduzione media del 48% del tasso di esacerbazioni gravi nel gruppo di pazienti trattati con BT rispetto all'anno prima di essere sottoposti a BT.
  • Nell'arco di cinque anni, è stata osservata una riduzione media dell'88% del tasso di visite in Pronto Soccorso per sintomi respiratori nel gruppo di pazienti trattati con BT rispetto all'anno prima di essere sottoposti a BT.
  • Il confronto delle immagini ottenute mediante tomografia computer
    '/>"/>

SOURCE Boston Scientific
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
2. AVTs Customer Medbox, Makes Wall Street Journal MarketWatch Headlines Again
3. Journal ONCOLOGY and CancerNetwork Now Bringing Readers Select ACR Appropriateness Criteria
4. CVS Caremark Uses Data to Combat National Prescription Drug Abuse Epidemic; Program Details Published in New England Journal of Medicine Online
5. Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
6. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
7. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
8. Philadelphia Business Journal has named Hope Paige Medical ID one of its Best Places to Work in Philadelphia
9. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
10. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
11. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 /PRNewswire/ ... company") announced today that the company,s board of directors approved ... to June 30. Accordingly, DelMar will file a Transition Form ... Jeffrey Bacha , president and CEO of DelMar stated, "The ... achieving our goal of obtaining a senior exchange listing for ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % ... , India Business grew by 20.87% to Rs. 3,971.59 ... Mn Rest of World (ROW) Business grew by 20.67% ... 34.53% to Rs. 977.26 Mn Latin America Business grew ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today announced ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4
(Date:7/24/2014)... Journal of Oral Implantology —Success of a ... the alveolar ridge—an indication of the amount of bone ... exist, each with their own advantages, to determine bone ... highlighted as a strategy for treating horizontally collapsed alveolar ... comparison of two commonly used techniques , the ...
(Date:7/24/2014)... bearing human breast tumors, exposure to dim light at ... drug tamoxifen, according to data published in Cancer ... Cancer Research. The negative effects of dim light exposure ... melatonin supplement during the night. , "Resistance to tamoxifen ... breast cancer," said Steven M. Hill, PhD, professor of ...
(Date:7/24/2014)... 2014 Vulnerable populations such as ... are disproportionately affected by food security, despite the ... the United States, according to a new report ... the Consolidated Appropriations Act, 2014 (P.L. 113-76), Congress ... Nutrition Service (FNS) to contract with a nonprofit ...
(Date:7/24/2014)... July 24, 2014 In a July 9th ... and founder of Lotus Blossom Consulting LLC , was ... Three Ways to Cut the High Cost of Infertility ... minimize costs is to maximize your chance of success from ... choosing a clinic. , “I am always happy to ...
(Date:7/24/2014)... appears to increase the risk for head and neck cancer ... with DM, but the risk of HNC in patients with ... cancer is the sixth most common type of cancer. It ... an estimated 650,000 new cancer cases and 350,000 cancer deaths ... Insurance Research Database to examine the risk of HNC in ...
Breaking Medicine News(10 mins):Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3
... daytime sleepiness when opening bell is pushed back, study concludes ... schools have a delayed start time sleep longer and report ... Center in Connecticut. , The study included 259 high school ... with a mean bed time of 10:52 p.m. and a ...
... June 12, 2008 -- Biogen Idec will ... first dual-mechanism, lymphotoxin-; (LT-;) and LIGHT pathway inhibitor ... including rheumatoid arthritis (RA), during the 2008 European ... Rheumatology at the Le Palais de Congrs de ...
... to optimize health, SAN FRANCISCO, June ... that more dehydration occurs during the active ... increase. For most,people, dehydration may be prevented ... day -- a practice, say experts, that ...
... and Q2 2007 Levels, - STAAR Announces Internet Marketing Campaign ... ... MONROVIA, Calif., June 12 STAAR Surgical,Company (Nasdaq: STAA ), ... that Visian ICL(TM),(Implantable Collamer Lens) sales in the U.S. for the second ...
... months ago, members of,Congress asked the Social Security Commission ... age. "A lot of seniors had the,idea that Medicare ... of LTC Financial Partners LLC (LTCFP), one of the ... "It wasn,t,so, but the wording of the Social Security ...
... Studies on the Value of Drug-Disease, Modeling ... Agents, MOUNTAIN VIEW, Calif., June 12 ... of software, strategic,consulting, and regulatory services for optimizing ... senior scientist,Pharsight Strategic Consulting Services, will speak to ...
Cached Medicine News:Health News:Teens Sleep Longer With Delayed School Starts 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 3Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 4Health News:Hydration Is Key to Maintaining Health During Hot Summer Months 2Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 2Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 3Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 4Health News:Social Security Statement Advises Seniors to Consider Private Long-Term Care Insurance, LTC Agency Reports; Medicare Won't Cover It 2Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 2Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: